Brenda Chyla

2 ta ish

AbbVie (United States)

1. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

   Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo +15

   MaqolaOAOchiq kirish20242 iqtibos

   ABIABI:AkademIndex/2026.other.244235

2. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

   Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat +13

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.312643